Silverback Therapeutics Inc. (SBTX): Price and Financial Metrics
SBTX Price/Volume Stats
| Current price | $5.87 | 52-week high | $8.97 |
| Prev. close | $5.81 | 52-week low | $2.80 |
| Day low | $5.72 | Volume | 116,700 |
| Day high | $6.15 | Avg. volume | 337,931 |
| 50-day MA | $5.39 | Dividend yield | N/A |
| 200-day MA | $4.38 | Market Cap | 211.66M |
SBTX Stock Price Chart Interactive Chart >
Silverback Therapeutics Inc. (SBTX) Company Bio
Silverback Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Its lead product candidate is SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers. The company also focuses on developing SBT6290, a product candidate that is in preclinical stage, which is a TLR8 linker-payload conjugated to a monoclonal antibody that targets Nectin4, which is expressed in bladder, triple negative breast, head and neck, and non-small cell lung cancers. In addition, it engages in developing SBT8230, a TLR8 linker-payload conjugated to an ASGR1 monoclonal antibody that is under development for the treatment of chronic hepatitis B virus infection; and agents that localize therapies to modulate pathways in additional oncology and fibrosis indications using TLR8 and other linker-payloads. Silverback Therapeutics, Inc. was founded in 2016 and is headquartered in Seattle, Washington.
Latest SBTX News From Around the Web
Below are the latest news stories about SILVERBACK THERAPEUTICS INC that investors may wish to consider to help them evaluate SBTX as an investment opportunity.
Once A Cancer Company, Silverback Merges With Small Biotech Working On Allergy TreatmentARS Pharmaceuticals Inc will merge with Silverback Therapeutics Inc (NASDAQ: SBTX) in an all-stock transaction, with a new entity operating under the ARS Pharmaceuticals name and trade on NASDAQ under the SPRY symbol. The combined company will focus on neffy, ARS's investigational epinephrine nasal spray for Type I allergic reactions, including anaphylaxis. The combined entity is expected to have approximately $265 million in cash and equivalents at closing. Also Read: Silverback Therapeutics Ax |
Silverback Therapeutics and ARS Pharmaceuticals Announce MergerSEATTLE & SAN DIEGO, July 21, 2022--Silverback Therapeutics, Inc. (Nasdaq: SBTX) ("Silverback") and ARS Pharmaceuticals, Inc. ("ARS") today announced that the companies have entered into a definitive agreement under which ARS will merge with Silverback in an all-stock transaction. The combined company will focus on the potential regulatory approval and commercialization of neffy, ARS’s investigational epinephrine nasal spray for the treatment of Type I allergic reactions including anaphylaxis. T |
What You Need To Know About Silverback Therapeutics, Inc.'s (NASDAQ:SBTX) Investor CompositionThe big shareholder groups in Silverback Therapeutics, Inc. ( NASDAQ:SBTX ) have power over the company. Large... |
Silverback Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment ConferenceSEATTLE, May 17, 2022--Silverback Therapeutics, Inc. (Nasdaq: SBTX) ("Silverback"), a biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases, today announced that Silverback management will participate in the H.C. Wainwright 24th Global Investment Conference from May 23-25, 2022. |
JonesTrading Keeps Their Hold Rating on Silverback Therapeutics (SBTX)JonesTrading analyst Soumit Roy maintained a Hold rating on Silverback Therapeutics (SBTX – Research Report) on May 13. The company's shares closed last Friday at $2.96, close to its 52-week low of $2.80. According to TipRanks.com, Roy is a 3-star analyst with an average return of 3.2% and a 28.5% success rate. Roy covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Adaptimmune Therapeutics, and Actinium Pharmaceuticals. The word on The Street in general, suggests a Hold analyst consensus rating for Silverback Therapeutics with a $3.43 average price target, an 11.0% upside from current levels. In a report issued on May 13, H.C. |
SBTX Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | -84.05% |
| 5-year | N/A |
| YTD | N/A |
| 2023 | N/A |
| 2022 | 0.00% |
| 2021 | -85.63% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...